In this work, we showed that head and neck squamous cell carcinoma (HNSCC) cells exposed to cetuximab, monoclonal antibody targeting EGFR, can modulate EGFR expression of MVs. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.